Maximize the Therapeutic Potential of Novel RAS Targeted Therapies Through Effectively Drugging All Mutations Beyond G12C, Advancing Emerging Combinations Therapies & Finally Defeat Resistance to Anti-RAS Drugs

4th RAS-Targeted Drug Development Summit 
Expanding the Therapeutic Landscape of Druggable RAS-Mutant Cancers 

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.

The 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before, we will unite 280+ experts to showcase 4-days of exclusive, never shared before data as we delve into accelerating discovery and emerging strategies, optimizing translation and pre-clinical development, and advancing the landscape of clinical trials for combinations and monotherapies.

With mounting success in targeted RAS drugs, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data, expert insight, and exclusive discussions with global leaders, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C, G12D, and G12V. Continuing to advance valuable combination therapies into the clinic, and finally, crack resistance to RAS targeted therapeutics.

This year’s forum returns as the only industry-focused event wholly dedicated to RAS-mutant cancers. With this, we will be uniting all experts from across the globe to spend 4 days in Boston, learning, discussing, and progressing anti-RAS therapies to the patent.

300+ Attendees

80+ World-Class Speakers

45+ Late-Breaking Case Studies

15+ Hours of Networking

9 Dedicated Workshops

3 Streams of Content

A Snapshot of our Expert Speaker Faculty

Group Discounts Available

Group Discounts - JAK & Innate Immune (12)

Multi-Pass Discount

10% Discount – 3+ Passes
15% Discount – 6+ Passes
20% Discount – 9+ Passes

A Snapshot of 2021 Attendees

Companies attending - RAS